Advising Panmure Gordon on £6 million placing for biopharmaceutical group Arecor Therapeutics

We have advised investment bank Panmure Gordon, as Nominated adviser and broker, on a £6m placing for globally focused biopharmaceutical group, Arecor Therapeutics plc.

The placing was conducted by way of an accelerated book building process, and the proceeds will be used to support the acquisition of Tetris Pharma, a commercial stage speciality pharmaceutical company which is expected to add a key commercial diabetes product to Arecor's portfolio.

Commenting on the transaction, Freddy Crossley, Managing Director at Panmure Gordon, said: "We appreciated the diligent, professional and above all pragmatic and commercial support we got from Ross and the team at Taylor Wessing to help execute the fundraise and this exciting acquisition for Arecor.”

The team was led by corporate partner Ross McNaughton with support from senior associate Tom Benjamin.